Acerus Announces Launch of NATESTO® Specialty Sales Team in the United States

Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Jul 20, 2020 07:30 am

Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF), a specialty pharmaceutical company focused on the commercialization of novel prescription products for men’s health, today announced the launch of a dedicated sales team to promote the Company’s key product, NATESTO® (testosterone nasal gel), to urologists and endocrinologists across the United States.

The 22 specialty sales representatives will target high-prescribing (decile 6-10) medical practitioners who currently treat men with hypogonadism. Acerus, in partnership with Syneos Health, has equipped its U.S. team with a suite of digital technologies that will allow reps to conduct virtual meetings and customer engagements, given varying state rules regarding COVID-19 restrictions. In addition, as per the terms of the revised partnership agreement between Acerus and Aytu BioScience, Aytu will focus their own U.S. sales team (currently comprised of some 33 representatives) on the promotion of NATESTO® to high-prescribing primary care physicians who treat men with hypogonadism.

“The launch of the Acerus Specialty Sales team in the United States is a significant milestone in the commercialization of NATESTO®,” said Ed Gudaitis, President and Chief Executive Officer of Acerus. “By adding dedicated resources – focused on high-prescribing urologists and endocrinologists – we should see increased awareness, interest, and adoption of NATESTO®. This sales force expansion, combined with ongoing improvements in insurance coverage and the work being done by Aytu, will set the stage for success in 2020 and beyond.”

About Acerus

Acerus Pharmaceuticals Corporation is a Canadian-based specialty pharmaceutical company focused on the commercialization and development of innovative prescription products that improve patient experience, with a primary focus in the field of men’s health. The Company commercializes its products via its own salesforce in the United States and Canada, and through a global network of licensed distributors in other territories.

Acerus’ shares trade on TSX under the symbol ASP and on OTCQB under the symbol ASPCF. For more information, visit and follow us on Twitter and LinkedIn.

Notice Regarding Forward-Looking Statements

Information in this press release that is not current or historical factual information may constitute forward looking information within the meaning of securities laws. Implicit in this information are assumptions regarding our future operational results. These assumptions, although considered reasonable by the company at the time of preparation, may prove to be incorrect. Readers are cautioned that actual performance of the company is subject to a number of risks and uncertainties, including with respect to the impact of the Acerus sales force and increased insurance coverage on the commercial potential of NATESTO® in the U.S., and could differ materially from what is currently expected as set out above. In particular, these assumptions include but are not limited to, the following: the COVID-19 pandemic will not affect our business plan and that of our suppliers, the COVID-19 pandemic will not last many months and health care professionals will be available to hear about our products and to continue education programs related to them. For more exhaustive information on these risks and uncertainties you should refer to our annual information form dated March 3, 2020 which is available at Forward-looking information contained in this press release is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. You should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any particular time, whether as a result of new information, future events or otherwise, except as required by applicable securities law.

Company Contact
[email protected]

Investor Relations Contact
Chris Witty
Acerus Investor Relations
(646) 438-9385
[email protected]

Comment On!

Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to (via Easy Blurb).